Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. (NASDAQ: CHRS) is a commercial-stage oncology company whose news flow is centered on its PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and a proprietary immuno-oncology pipeline. Company announcements frequently highlight clinical data, regulatory developments, financial results and strategic updates related to its antibody-based cancer therapies.
News about Coherus Oncology often covers LOQTORZI in nasopharyngeal carcinoma (NPC), including long-term survival data from the JUPITER-02 Phase 3 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic NPC. Releases also describe LOQTORZI’s approved indications in the United States and its role as the only FDA-approved and available treatment for recurrent, locally advanced or metastatic NPC across all patient subsets and lines of therapy.
Investors and clinicians following CHRS can expect regular updates on pipeline programs such as CHS-114 and casdozokitug. Coherus reports biomarker and proof-of-mechanism data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, in head and neck squamous cell carcinoma and other solid tumors, as well as clinical and translational findings for casdozokitug, a novel IL-27 antagonist in advanced solid tumors including hepatocellular carcinoma and non-small cell lung cancer.
The company’s news stream also includes quarterly financial results, business updates, participation in major healthcare and oncology conferences, and investor-focused events. These items provide context on revenue trends for LOQTORZI, research and development spending on its immuno-oncology programs, and corporate strategy.
For market participants tracking CHRS, the Coherus Oncology news page on Stock Titan aggregates these press releases and related coverage, offering a centralized view of clinical milestones, regulatory disclosures and financial communications that can influence perceptions of the company’s oncology franchise and pipeline progress.
Coherus BioSciences (NASDAQ: CHRS) has announced its participation in four upcoming investor conferences in May and June 2025:
- Citizens Life Science Conference (May 8, NY)
- HCW BioConnect @ Nasdaq NYC 2025 (May 20, NY)
- TD Cowen 6th Annual Oncology Innovation Summit (May 27, Virtual)
- Jefferies Global Healthcare Conference (June 4, NY)
All presentations will be accessible via webcasts through the company's investor relations website, with replays available for 30 days. One-on-one meetings with management can be arranged through respective bank representatives.
Coherus BioSciences (NASDAQ: CHRS) presented promising Phase 1 clinical trial data for CHS-114, their selective anti-CCR8 antibody, in combination with toripalimab for head and neck squamous cell carcinoma (HNSCC) treatment at AACR 2025.
Key findings include:
- Confirmed partial response in a heavily pretreated PD-1 refractory patient
- >50% depletion in CCR8+ Treg cells
- Significant increase in CD8+ T cells
- Manageable safety profile consistent with advanced disease
The study evaluated CHS-114 as monotherapy and in combination with toripalimab in 21 patients with advanced solid tumors. A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing, with results expected in first half of 2026.
Coherus BioSciences (NASDAQ: CHRS) has completed the divestiture of its UDENYCA® franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million. The transaction includes an upfront payment of $483.4 million (with $118.4 million for UDENYCA inventory) and potential milestone payments of up to $75 million.
The deal provides Coherus with a $250 million post-close cash balance, extending runway into 2027. The company will now focus exclusively on innovative oncology programs including:
- LOQTORZI® - a revenue-generating PD-1 inhibitor
- Casdozokitug - a first-in-class IL-27 antagonist
- CHS-114 - a selective CCR8 antibody
The transaction closed on April 11, 2025, with Accord BioPharma, Intas' U.S. specialty division, assuming full responsibility for the UDENYCA franchise in the U.S.
Coherus BioSciences (NASDAQ: CHRS) has announced plans to repurchase approximately $170 million of its 1.500% Convertible Senior Subordinated Notes due 2026 through privately negotiated transactions. The repurchase will be executed at 100% of principal amount plus accrued interest.
The repurchase is contingent on the closing of the previously announced UDENYCA franchise divestiture to Intas Pharmaceuticals Following this initial repurchase, about $60 million in convertible notes will remain outstanding, which Coherus intends to repurchase after the transaction closes.
Additionally, holders representing a majority of the outstanding notes have agreed to provide consent for amendments to the indenture, allowing the UDENYCA divestiture to proceed.
Coherus BioSciences (NASDAQ: CHRS) has announced the upcoming presentation of interim data from its ongoing Phase 1 clinical trial of CHS-114, a selective, cytolytic anti-CCR8 antibody, at the 2025 AACR Annual Meeting. The study evaluates CHS-114 both as a monotherapy and in combination with toripalimab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The presentation, led by Dr. Francis Worden from the University of Michigan, will be featured as a poster (Abstract #CT038) in the Phase 0 and Phase 1 Clinical Trials section. The session is scheduled for Monday, April 28, 2025, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place Convention Center in Chicago.
Coherus BioSciences (CHRS) reported its Q4 and full year 2024 results, with annual net revenue increasing 4% to $267.0 million. The company's transformation highlights include strong performance of key products: UDENYCA® net revenue grew 62% year-over-year, while LOQTORZI® sales increased 29% quarter-over-quarter.
A significant development is the planned UDENYCA divestiture for up to $558.4 million, expected to close in late Q1 or early Q2 2025. Post-divestiture, Coherus projects approximately $250 million in cash, providing a runway exceeding two years. The company plans to reduce headcount by 30% to about 155 employees.
The company's focus shifts to oncology, with LOQTORZI receiving preferred status in NCCN guidelines for nasopharyngeal carcinoma treatment. Multiple clinical data readouts are expected across their oncology pipeline in 2025/2026, including developments in casdozokitug and CHS-114 programs.
Coherus BioSciences (NASDAQ: CHRS) has scheduled its fourth quarter and full year 2024 financial results announcement for March 10, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. ET on the same day, where management will discuss financial results and provide a business update.
Investors and interested parties can pre-register for the conference call through a provided link to receive dial-in information and a personal PIN. A live webcast will be available, and both the press release containing the financial results and an archived version of the webcast will be accessible through the company's investor relations website.
Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference. The company will engage in a fireside chat presentation scheduled for Tuesday, March 4, 2025, at 11:50 a.m. Eastern time.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events and Presentations' section of Coherus' investor website. The presentation recording will remain available for approximately 90 days following the event on the company's investor portal at https://investors.coherus.com/events-presentations.
Coherus BioSciences (NASDAQ: CHRS) announced final Phase 2 clinical trial data for casdozokitug (casdozo) in combination with atezolizumab and bevacizumab for treating hepatocellular carcinoma (HCC). The trial showed improved results with an overall response rate of 38% (up from 27%) and complete response rate of 17.2% (up from 10.3%).
The study involved 30 treatment-naïve patients with unresectable locally advanced or metastatic HCC. Key findings include median progression-free survival of 8.1 months and disease control rate of 58.6% under RECIST v1.1 criteria. The treatment demonstrated efficacy across both viral and non-viral disease types with no new safety concerns.
Based on these promising results, Coherus has initiated a new randomized Phase 2 study combining casdozo with bevacizumab and toripalimab, expected to enroll up to 72 patients.